IMMUNOTHERAPEUTIC FORMULATIONS WITH INTERLEUKIN-2-NEUTRALISING CAPACITY

摘要

The invention relates to pharmaceutical formulations which can be used in
relation to cancer and which block the binding of Interleukin 2 (IL-2) to the
receptor thereof. More specifically, the invention relates to therapeutic
formulations that can increase the immunogenicity of IL-2 by coupling same to
transport protein P64k of Neisseria meningitidis in adjuvant Montanide ISA 51
for the induction of autoantibodies that block the binding of IL-2 to the
receptor thereof. The invention also relates to effective methods for the
treatment of tumours, including breast cancer. The invention further relates
to the therapeutic combination of the IL-2-based vaccine with other cancer
vaccines based on specific antigens of tumours or tumour growth factors, as
well as radiotherapy or chemotherapeutic medicaments that are traditionally
used in oncological practice.